Global pharma titan navigating deals, investments and science leadership
GDP has risen by 0.1% in May, driven by services though production and construction slipped. The upside comes amid ongoing Middle East tensions and ahead of a new prime minister taking office, with analysts noting fragile momentum and potential inflation risks.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.